$LXRP ---
"We are in the process of applying to have our common stock and warrants sold in this offering listed on the Nasdaq Capital Market (“Nasdaq”) under the symbols“LEXX” and “LEXXW”, respectively. There is no assurance that our listing application will be approved".
Recent Interview with Chris Bunka:
Industry analyst Ted Ohashi may have been thinking about BAT and Lexaria making oral vaccines during a recent interview he did with Chris Bunka.
"Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) was faced with a puzzling situation last week. A COVID19 vaccine made from tobacco leaves is being developed by British American Tobacco (LON: BATS) biotech arm Kentucky BioProcessing. BATS claims it will be able to produce 1 – 3 million doses per week with the support of government and manufacturers. BATS already received approval for Phase 1 trials which means they can begin testing on human subjects for both a COVID-19 and seasonal influenza vaccine. BATS says results are likely by mid-2021.
What is intriguing is that in Let’s Toke Business (Ted Ohashi's newsletter), dated September 4, 2020, he reported that LXRP had entered into a research agreement with BATS because one of the world’s largest tobacco companies wanted to test LXRP’s DehydraTECH™ technology for an undisclosed application. Since LXRP was already in an agreement with Altria (NYSE: MO) to test how DehydraTECH™ impacts the oral delivery of nicotine, Ohashi assumed the BATS testing had a similar goal.
However, I recall Chris Bunka saying at the time that it was a BATS research project and they had not disclosed what they were testing. Thus, when I saw the most recent newsletter, I couldn't help but wonder if it was possibly BATS that is testing for use with their own COVID vaccine (this would be a really big deal).
Ohashi did ask Chris Bunka about the current report and received the following answer:
“I think it’s more likely that BATS is interested in DehydraTECH™ for nicotine delivery”
If you notice, this is not a negative answer, but merely a I can't say. What is so exciting about the DehydraTech technology is that it is extremely flexible in terms of potential applications --- another reason to like Lexaria".
https://4495825a-d729-4d8f-ade8-e78f828e1c8d....f2f36b.pdf
"We are in the process of applying to have our common stock and warrants sold in this offering listed on the Nasdaq Capital Market (“Nasdaq”) under the symbols“LEXX” and “LEXXW”, respectively. There is no assurance that our listing application will be approved".
Recent Interview with Chris Bunka:
Industry analyst Ted Ohashi may have been thinking about BAT and Lexaria making oral vaccines during a recent interview he did with Chris Bunka.
"Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) was faced with a puzzling situation last week. A COVID19 vaccine made from tobacco leaves is being developed by British American Tobacco (LON: BATS) biotech arm Kentucky BioProcessing. BATS claims it will be able to produce 1 – 3 million doses per week with the support of government and manufacturers. BATS already received approval for Phase 1 trials which means they can begin testing on human subjects for both a COVID-19 and seasonal influenza vaccine. BATS says results are likely by mid-2021.
What is intriguing is that in Let’s Toke Business (Ted Ohashi's newsletter), dated September 4, 2020, he reported that LXRP had entered into a research agreement with BATS because one of the world’s largest tobacco companies wanted to test LXRP’s DehydraTECH™ technology for an undisclosed application. Since LXRP was already in an agreement with Altria (NYSE: MO) to test how DehydraTECH™ impacts the oral delivery of nicotine, Ohashi assumed the BATS testing had a similar goal.
However, I recall Chris Bunka saying at the time that it was a BATS research project and they had not disclosed what they were testing. Thus, when I saw the most recent newsletter, I couldn't help but wonder if it was possibly BATS that is testing for use with their own COVID vaccine (this would be a really big deal).
Ohashi did ask Chris Bunka about the current report and received the following answer:
“I think it’s more likely that BATS is interested in DehydraTECH™ for nicotine delivery”
If you notice, this is not a negative answer, but merely a I can't say. What is so exciting about the DehydraTech technology is that it is extremely flexible in terms of potential applications --- another reason to like Lexaria".
https://4495825a-d729-4d8f-ade8-e78f828e1c8d....f2f36b.pdf
3
